TNFRSF10D and prostate carcinoma: Physiologically, DCR2 is frequently expressed in normal tissues, but often silenced by hypermethylation in a wide range tumour cells including breast cancer, cervical cancer, malignant mesothelioma, neuroblastoma and prostate cancer [28].